MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2097388
下载链接
链接失效反馈官方服务：
资源简介：
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
创建时间：
2011-01-15
